Cancer Epidemiology
Volume 34, Issue 2 , Pages 131-135 , April 2010

Male pattern baldness and prostate cancer risk in a population-based case–control study

  • Jonathan L. Wright

      Affiliations

    • Department of Urology, University of Washington School of Medicine, Seattle, WA, United States
    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    • Corresponding Author InformationCorresponding author at: Public Heath Sciences, Fred Hutchison Cancer Research Center, 1100 Fairview Avenue North, M4-B874 Seattle, WA 98109-1024, United States. Tel.: +1 206 543 3640; fax: +1 206 543 3272.
    • ,
  • Stephanie T. Page

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States
    • ,
  • Daniel W. Lin

      Affiliations

    • Department of Urology, University of Washington School of Medicine, Seattle, WA, United States
    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    • ,
  • Janet L. Stanford

      Affiliations

    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    • Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, United States

,Accepted 5 February 2010.

References 

  1. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1–11
  2. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol. 2003;121(6):1561–1564
  3. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116(3):452–455
  4. Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, Sutherland RL, et al. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev. 2005;14(4):993–996
  5. Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S, Steffens M, Flaquer A, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet. 2008;40(11):1279–1281
  6. Richards JB, Yuan X, Geller F, Waterworth D, Bataille V, Glass D, et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet. 2008;40(11):1282–1284
  7. Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci. 2004;34(1):11–16
  8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–1191
  9. Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13(3):158–168
  10. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–224
  11. Demark-Wahnefried W, Lesko SM, Conoway MR, RObertson CN, Clark RV, Lobaugh B, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl. 1997;18(5):495–500
  12. Denmark-Wahnefried W, Schildkraut JM, Thompson D, Lesko SM, McIntyre L, Schwingl P, et al. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9(3):325–328
  13. Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case–control study. Cancer Epidemiol Biomarkers Prev. 2002;11(6):549–553
  14. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000;9(5):523–527
  15. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168(3):250–260
  16. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al. SEER cancer statistics review, 1975–2005, based on November 2007 SEER data submission, posted to the SEER web site. Bethesda, MD: Institute NC; 2008;
  17. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men, Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–731
  18. Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, et al. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 2007;120(4):776–780
  19. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296–300
  20. Choi MH, Yoo YS, Chung BC. Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness. J Invest Dermatol. 2001;116(1):57–61
  21. Camacho FM, Garcia-Hernandez MJ, Fernandez-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. Br J Dermatol. 2008;158(5):1121–1124
  22. Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol. 2006;154(4):730–734
  23. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol. 2004;92(4):221–236
  24. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci. 1996;1:d59–d71
  25. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198(1–2):51–59
  26. Zhu YS, Sun GH. 5alpha-Reductase isozymes in the prostate. J Med Sci. 2005;25(1):1–12
  27. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578–589
  28. Chen W, Yang CC, Chen GY, Wu MC, Sheu HM, Tzai TS. Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res. 2004;296(6):245–249
  29. Oh BR, Kim SJ, Moon JD, Kim HN, Kwon DD, Won YH, et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology. 1998;51(5):744–748
  30. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50(1):169–173
  31. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57(5):930–935
  32. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170–183
  33. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993;150(5 Pt 2):1736–1739
  34. Taylor R, Matassa J, Leavy JE, Fritschi L. Validity of self reported male balding patterns in epidemiological studies. BMC Public Health. 2004;4:60

PII: S1877-7821(10)00021-4

doi: 10.1016/j.canep.2010.02.003

Cancer Epidemiology
Volume 34, Issue 2 , Pages 131-135 , April 2010

Article Tools

* Image Usage & Resolution